Hepatitis C Articles (HCV)
Back
	Epclusa European Commission - SUMMARY OF PRODUCT CHARACTERISTICS        Download the PDF here   European Commission Grants Marketing Authorization for Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C - (07/10/16)   Epclusa SUMMARY OF PRODUCT CHARACTERISTICS   Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1).   The recommended dose of Epclusa is one tablet, taken orally, once daily with or without food (see section 5.2).           View Older Articles   Back to Top   www.natap.org